Language
English
Publication Date
12-1-2025
Journal
Journal of Immunology
DOI
10.1093/jimmun/vkaf263
PMID
41166719
PMCID
PMC12726064
PubMedCentral® Posted Date
10-30-2025
PubMedCentral® Full Text Version
Post-print
Abstract
The National Institutes of Health-funded IMPACC (IMmunoPhenotyping Assessment in a COVID-19 Cohort) evaluated longitudinal clinical and immunological features of human patients hospitalized for COVID-19. This study focuses on comparing the novel NULISAseq assay with the Olink platform using a subset of participants to assess their efficacy in predicting COVID-19 severity and understanding immune response dynamics. Our findings reveal that NULISAseq could provide superior detectability and dynamic range across various targets. Elastic net analysis demonstrated that specific proteins, including amphiregulin, effectively predict COVID-19 severity from sera at admission (samples drawn within 96 h of admission), with a test area under the curve of 0.84. Longitudinal analysis identified significant differences in multiple targets, including IL-5 and interferons, between low- and high-severity groups over time. Additionally, association rule mining suggested potential early markers predictive of later immune cell changes. These findings emphasize the potential of NULISAseq for comprehensive profiling, early prediction, and identification of targeted therapeutic interventions in COVID-19.
Keywords
Humans, COVID-19, SARS-CoV-2, Severity of Illness Index, Male, Middle Aged, Female, Adult, Aged, Immunophenotyping, Longitudinal Studies, Biomarkers, cytokines, human, inflammation, molecular biology, viral
Published Open-Access
yes
Recommended Citation
Abe, Koji; Holmes, Tyson H; Nguyen, Tran T; et al., "Evaluating Covid-19 Severity Prediction and Immune Dynamics With NULISAseq: Insights From the IMPACC Study" (2025). Faculty, Staff and Students Publications. 6113.
https://digitalcommons.library.tmc.edu/baylor_docs/6113